Back


26/09/2018
Minoryx Therapeutics raises €21.3M in Series B funding round
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the completion of a Series B funding round of €21.3M. The proceeds will enable the company to expand the list of indications for its lead compound, MIN-102, as well as to conduct a new clinical trial for a second orphan central nervous system (CNS) indication. [...]

Download the pdf file





X

X